145 related articles for article (PubMed ID: 21127401)
1. Differential role of CD133 and CXCR4 in renal cell carcinoma.
D'Alterio C; Cindolo L; Portella L; Polimeno M; Consales C; Riccio A; Cioffi M; Franco R; Chiodini P; Cartenì G; Mirone V; Longo N; Marra L; Perdonà S; Claudio L; Mascolo M; Staibano S; Falsaperla M; Puglisi M; Martignoni G; Ficarra V; Castello G; Scala S
Cell Cycle; 2010 Nov; 9(22):4492-4500. PubMed ID: 21127401
[TBL] [Abstract][Full Text] [Related]
2. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.
Zhang SS; Han ZP; Jing YY; Tao SF; Li TJ; Wang H; Wang Y; Li R; Yang Y; Zhao X; Xu XD; Yu ED; Rui YC; Liu HJ; Zhang L; Wei LX
BMC Med; 2012 Aug; 10():85. PubMed ID: 22871210
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
[TBL] [Abstract][Full Text] [Related]
4. Finding markers for cancer stem cells in renal cell carcinoma: looking beyond CD133.
Ottaiano A
Cell Cycle; 2010 Nov; 9(22):4431. PubMed ID: 21088484
[No Abstract] [Full Text] [Related]
5. CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.
Costa WH; Rocha RM; Cunha IW; Fonseca FP; Guimaraes GC; Zequi Sde C
World J Urol; 2012 Aug; 30(4):553-8. PubMed ID: 21969131
[TBL] [Abstract][Full Text] [Related]
6. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.
Kim K; Ro JY; Kim S; Cho YM
Hum Pathol; 2012 Dec; 43(12):2109-16. PubMed ID: 22944295
[TBL] [Abstract][Full Text] [Related]
7. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α).
Sun C; Song H; Zhang H; Hou C; Zhai T; Huang L; Zhang L
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1619-24. PubMed ID: 22614155
[TBL] [Abstract][Full Text] [Related]
8. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis.
Silinsky J; Grimes C; Driscoll T; Green H; Cordova J; Davis NK; Li L; Margolin DA
J Surg Res; 2013 Nov; 185(1):113-8. PubMed ID: 23777983
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
[TBL] [Abstract][Full Text] [Related]
10. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.
Bertolini G; D'Amico L; Moro M; Landoni E; Perego P; Miceli R; Gatti L; Andriani F; Wong D; Caserini R; Tortoreto M; Milione M; Ferracini R; Mariani L; Pastorino U; Roato I; Sozzi G; Roz L
Cancer Res; 2015 Sep; 75(17):3636-49. PubMed ID: 26141860
[TBL] [Abstract][Full Text] [Related]
11. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
Li XF; Guo XG; Yang YY; Liu AY
Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
[TBL] [Abstract][Full Text] [Related]
12. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
D'Alterio C; Consales C; Polimeno M; Franco R; Cindolo L; Portella L; Cioffi M; Calemma R; Marra L; Claudio L; Perdonà S; Pignata S; Facchini G; Cartenì G; Longo N; Pucci L; Ottaiano A; Costantini S; Castello G; Scala S
Curr Cancer Drug Targets; 2010 Nov; 10(7):772-81. PubMed ID: 20578990
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
15. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker.
Schneider M; Huber J; Hadaschik B; Siegers GM; Fiebig HH; Schüler J
BMC Cancer; 2012 Mar; 12():96. PubMed ID: 22433494
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
17. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
19. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.
Cioffi M; D'Alterio C; Camerlingo R; Tirino V; Consales C; Riccio A; Ieranò C; Cecere SC; Losito NS; Greggi S; Pignata S; Pirozzi G; Scala S
Sci Rep; 2015 May; 5():10357. PubMed ID: 26020117
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients.
Coco C; Zannoni GF; Caredda E; Sioletic S; Boninsegna A; Migaldi M; Rizzo G; Bonetti LR; Genovese G; Stigliano E; Cittadini A; Sgambato A
J Exp Clin Cancer Res; 2012 Sep; 31(1):71. PubMed ID: 22964035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
